{
    "nctId": "NCT01896050",
    "briefTitle": "Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer",
    "officialTitle": "A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Third-generation Aromatase Inhibitors and Tamoxifen",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Arthralgia, Obesity",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 115,
    "primaryOutcomeMeasure": "Effect of Change in Body Mass Index on Change in Grip Strength With Aromatase Inhibitor Therapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Stage 0-III breast cancer who are scheduled to receive endocrine therapy with tamoxifen or an aromatase inhibitor\n* All prior surgery and chemotherapy should be complete\n* Age 18 and above and postmenopausal\n\nExclusion Criteria:\n\n* Major rheumatologic disorders\n* Concomitant sex hormone containing drugs or Leutinizing Hormone Releasing Hormone agonist therapy\n* For those subjects initiating treatment with an aromatase inhibitor, prior tamoxifen within 4 weeks of enrollment\n* For those subjects initiating treatment with tamoxifen, prior aromatase inhibitor within 4 weeks of enrollment",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}